Study shows promise for iNKT cell platform to treat cancer
Allogeneic invariant natural killer T cells (allo-iNKTs) from a healthy donor have been shown to have therapeutic effects in treatment-resistant cancers and improve survival from COVID-19-related acute respiratory failure in previous studies. Unlike T cells, allo-iNKTs can be transferred from one person to another without causing graft-versus-host disease. But allo-iNKT cells rapidly become undetectable in the body after infusion, raising concerns over their rejection and disease relapse. Their functioning also varies from person to person.
Researchers from the School of Veterinary Medicine and Perelman School of Medicine hypothesized ...







